Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report

Purnima Singh, Xuexia Wang, Lindsey Hageman, Yanjun Chen, Tarek Magdy, Wendy Landier, Jill P. Ginsberg, Joseph P. Neglia, Charles A. Sklar, Sharon M. Castellino, Zoann E. Dreyer, Melissa M. Hudson, Leslie L. Robison, Javier G. Blanco, Mary V. Relling, Paul Burridge, Smita Bhatia*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: Anthracycline-related cardiomyopathy is a leading cause of late morbidity in childhood cancer survivors. Glutathione S-transferases (GSTs) are a class of phase II detoxification enzymes that facilitate the elimination of anthracyclines. As free-radical scavengers, GSTs could play a role in oxidative damage-induced cardiomyopathy. Associations between the GSTμ1 (GSTM1) null genotype and iron-overload–related cardiomyopathy have been reported in patients with thalassemia. Methods: The authors sought to identify an association between the GSTM1 null genotype and anthracycline-related cardiomyopathy in childhood cancer survivors and to corroborate the association by examining GSTM1 gene expression in peripheral blood and human-induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) from survivors with and without cardiomyopathy. GSTM1 gene deletion was examined by polymerase chain reaction in 75 survivors who had clinically validated cardiomyopathy (cases) and in 92 matched survivors without cardiomyopathy (controls). Conditional logistic regression analysis adjusting for sex, age at cancer diagnosis, chest radiation, and anthracycline dose was used to assess the association between genotype and cardiomyopathy. Proprietary bead array technology and quantitative real-time polymerase chain reaction were used to measure GSTM1 expression levels in samples from 20 cases and 20 matched controls. hiPSC-CMs from childhood cancer survivors (3 with cardiomyopathy, 3 without cardiomyopathy) also were examined for GSTM1 gene expression levels. Results: A significant association was observed between the risk of cardiomyopathy and the GSTM1 null genotype (odds ratio, 2.7; 95% CI, 1.3-5.9; P =.007). There was significant downregulation of GSTM1 expression in cases compared with controls (average relative expression, 0.67 ± 0.57 vs 1.33 ± 1.33, respectively; P =.049). hiPSC-CMs from patients who had cardiomyopathy revealed reduced GSTM1 expression (P =.007). Conclusions: The current findings could facilitate the identification of childhood cancer survivors who are at risk for anthracycline-related cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)4051-4058
Number of pages8
JournalCancer
Volume126
Issue number17
DOIs
StatePublished - Sep 1 2020

Keywords

  • anthracyclines
  • cardiomyopathy
  • childhood cancer survivors
  • gene expression
  • glutathione S-transferase 1 (GSTM1) null genotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report'. Together they form a unique fingerprint.

Cite this